Annual CFF
-$18.73 M
-$77.00 K-0.41%
31 December 2023
Summary:
BioMarin Pharmaceutical annual cash flow from financing activities is currently -$18.73 million, with the most recent change of -$77.00 thousand (-0.41%) on 31 December 2023. During the last 3 years, it has fallen by -$199.84 million (-110.34%). BMRN annual CFF is now -102.02% below its all-time high of $925.72 million, reached on 31 December 2015.BMRN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$499.13 M
-$511.74 M-4057.54%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly cash flow from financing activities is currently -$499.13 million, with the most recent change of -$511.74 million (-4057.54%) on 30 September 2024. Over the past year, it has dropped by -$498.34 million (-63240.74%). BMRN quarterly CFF is now -154.56% below its all-time high of $914.79 million, reached on 31 March 2015.BMRN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$518.47 M
-$498.34 M-2475.72%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM cash flow from financing activities is currently -$518.47 million, with the most recent change of -$498.34 million (-2475.72%) on 30 September 2024. Over the past year, it has dropped by -$499.77 million (-2672.84%). BMRN TTM CFF is now -153.85% below its all-time high of $962.83 million, reached on 30 June 2015.BMRN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.4% | -10000.0% | -2672.8% |
| 3 y3 years | -110.3% | -10000.0% | -36.2% |
| 5 y5 years | +95.2% | -10000.0% | -16.5% |
BMRN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -110.3% | at low | -3567.1% | at low | <-9999.0% | at low |
| 5 y | 5 years | -110.3% | +95.2% | -188.6% | at low | -194.0% | at low |
| alltime | all time | -102.0% | +95.2% | -154.6% | at low | -153.8% | at low |
BioMarin Pharmaceutical Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$499.13 M(-4057.5%) | -$518.47 M(+2475.7%) |
| June 2024 | - | $12.61 M(-129.5%) | -$20.13 M(-3.1%) |
| Mar 2024 | - | -$42.79 M(-494.8%) | -$20.78 M(+11.0%) |
| Dec 2023 | -$18.73 M(+0.4%) | $10.84 M(-1475.6%) | -$18.73 M(+0.2%) |
| Sept 2023 | - | -$788.00 K(-106.6%) | -$18.70 M(+80.3%) |
| June 2023 | - | $11.96 M(-129.4%) | -$10.37 M(-69.6%) |
| Mar 2023 | - | -$40.74 M(-474.8%) | -$34.11 M(+82.9%) |
| Dec 2022 | -$18.65 M(>+9900.0%) | $10.87 M(+44.1%) | -$18.65 M(+23.3%) |
| Sept 2022 | - | $7.54 M(-164.0%) | -$15.12 M(-36.2%) |
| June 2022 | - | -$11.78 M(-53.4%) | -$23.70 M(+2358.0%) |
| Mar 2022 | - | -$25.28 M(-275.6%) | -$964.00 K(+1908.3%) |
| Dec 2021 | -$48.00 K(-100.0%) | $14.40 M(-1496.3%) | -$48.00 K(-100.0%) |
| Sept 2021 | - | -$1.03 M(-109.4%) | -$380.60 M(+1.1%) |
| June 2021 | - | $10.95 M(-144.9%) | -$376.31 M(-313.3%) |
| Mar 2021 | - | -$24.36 M(-93.3%) | $176.43 M(-2.6%) |
| Dec 2020 | $181.12 M(-342.5%) | -$366.15 M(<-9900.0%) | $181.12 M(-67.1%) |
| Sept 2020 | - | $3.26 M(-99.4%) | $551.32 M(+1.0%) |
| June 2020 | - | $563.69 M(-2965.6%) | $546.08 M(-887.3%) |
| Mar 2020 | - | -$19.67 M(-586.7%) | -$69.36 M(-7.1%) |
| Dec 2019 | -$74.67 M(-80.8%) | $4.04 M(-304.7%) | -$74.67 M(-83.2%) |
| Sept 2019 | - | -$1.98 M(-96.2%) | -$445.08 M(+1.6%) |
| June 2019 | - | -$51.76 M(+107.2%) | -$437.95 M(+8.6%) |
| Mar 2019 | - | -$24.98 M(-93.2%) | -$403.22 M(+3.9%) |
| Dec 2018 | -$388.01 M(-176.5%) | -$366.36 M(-7212.4%) | -$388.01 M(+4438.6%) |
| Sept 2018 | - | $5.15 M(-130.2%) | -$8.55 M(-101.8%) |
| June 2018 | - | -$17.03 M(+74.4%) | $468.24 M(-7.1%) |
| Mar 2018 | - | -$9.77 M(-174.6%) | $504.12 M(-0.6%) |
| Dec 2017 | $507.14 M(-30.3%) | $13.10 M(-97.3%) | $507.14 M(-1.3%) |
| Sept 2017 | - | $481.94 M(+2455.9%) | $513.96 M(-33.2%) |
| June 2017 | - | $18.86 M(-379.6%) | $769.03 M(+1.5%) |
| Mar 2017 | - | -$6.74 M(-133.9%) | $757.63 M(+4.2%) |
| Dec 2016 | $727.11 M(-21.5%) | $19.91 M(-97.3%) | $727.11 M(+1.5%) |
| Sept 2016 | - | $737.00 M(+9787.4%) | $716.71 M(-4436.6%) |
| June 2016 | - | $7.45 M(-120.0%) | -$16.53 M(-37.2%) |
| Mar 2016 | - | -$37.26 M(-491.5%) | -$26.33 M(-102.8%) |
| Dec 2015 | $925.72 M(+402.6%) | $9.52 M(+152.8%) | $925.72 M(-3.3%) |
| Sept 2015 | - | $3.77 M(-260.1%) | $957.73 M(-0.5%) |
| June 2015 | - | -$2.35 M(-100.3%) | $962.83 M(+0.1%) |
| Mar 2015 | - | $914.79 M(+2103.1%) | $962.02 M(+422.3%) |
| Dec 2014 | $184.20 M(-75.3%) | $41.52 M(+368.1%) | $184.20 M(-78.3%) |
| Sept 2014 | - | $8.87 M(-380.8%) | $847.60 M(-0.4%) |
| June 2014 | - | -$3.16 M(-102.3%) | $851.03 M(-2.2%) |
| Mar 2014 | - | $136.96 M(-80.6%) | $869.81 M(+16.5%) |
| Dec 2013 | $746.67 M(+139.1%) | $704.93 M(+5631.6%) | $746.67 M(+818.3%) |
| Sept 2013 | - | $12.30 M(-21.3%) | $81.31 M(+2.5%) |
| June 2013 | - | $15.62 M(+13.0%) | $79.31 M(-74.6%) |
| Mar 2013 | - | $13.82 M(-65.1%) | $312.67 M(+0.1%) |
| Dec 2012 | $312.29 M(+964.5%) | $39.56 M(+283.9%) | $312.29 M(+10.3%) |
| Sept 2012 | - | $10.31 M(-95.9%) | $283.17 M(+0.9%) |
| June 2012 | - | $248.97 M(+1751.5%) | $280.62 M(+609.5%) |
| Mar 2012 | - | $13.45 M(+28.7%) | $39.55 M(+34.8%) |
| Dec 2011 | $29.34 M | $10.45 M(+34.6%) | $29.34 M(+232.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $7.76 M(-1.8%) | $8.82 M(+13.5%) |
| June 2011 | - | $7.90 M(+144.4%) | $7.78 M(-423.6%) |
| Mar 2011 | - | $3.23 M(-132.1%) | -$2.40 M(-168.6%) |
| Dec 2010 | $3.50 M(-105.5%) | -$10.07 M(-250.1%) | $3.50 M(-76.7%) |
| Sept 2010 | - | $6.71 M(-394.7%) | $15.02 M(+8.6%) |
| June 2010 | - | -$2.28 M(-124.9%) | $13.83 M(-125.6%) |
| Mar 2010 | - | $9.14 M(+531.2%) | -$53.99 M(-15.4%) |
| Dec 2009 | -$63.79 M(-379.7%) | $1.45 M(-73.8%) | -$63.79 M(+1.3%) |
| Sept 2009 | - | $5.52 M(-107.9%) | -$62.98 M(-4.5%) |
| June 2009 | - | -$70.10 M(>+9900.0%) | -$65.97 M(-783.5%) |
| Mar 2009 | - | -$653.00 K(-129.0%) | $9.65 M(-57.7%) |
| Dec 2008 | $22.81 M(-93.0%) | $2.25 M(-11.4%) | $22.81 M(-4.4%) |
| Sept 2008 | - | $2.54 M(-54.0%) | $23.87 M(-9.0%) |
| June 2008 | - | $5.52 M(-55.9%) | $26.24 M(-92.2%) |
| Mar 2008 | - | $12.51 M(+278.3%) | $337.38 M(+3.9%) |
| Dec 2007 | $324.57 M(+9.7%) | $3.31 M(-32.6%) | $324.57 M(+0.7%) |
| Sept 2007 | - | $4.91 M(-98.5%) | $322.36 M(+0.6%) |
| June 2007 | - | $316.67 M(<-9900.0%) | $320.44 M(-2040.5%) |
| Mar 2007 | - | -$310.00 K(-128.3%) | -$16.51 M(-105.6%) |
| Dec 2006 | $295.94 M(+883.6%) | $1.10 M(-63.3%) | $295.94 M(+0.2%) |
| Sept 2006 | - | $2.99 M(-114.7%) | $295.30 M(-15.7%) |
| June 2006 | - | -$20.29 M(-106.5%) | $350.50 M(-1.7%) |
| Mar 2006 | - | $312.14 M(>+9900.0%) | $356.73 M(+1085.7%) |
| Dec 2005 | $30.09 M(-207.9%) | $459.00 K(-99.2%) | $30.09 M(+84.9%) |
| Sept 2005 | - | $58.19 M(-513.7%) | $16.27 M(-128.6%) |
| June 2005 | - | -$14.07 M(-3.0%) | -$56.94 M(+34.0%) |
| Mar 2005 | - | -$14.50 M(+8.5%) | -$42.50 M(+52.4%) |
| Dec 2004 | -$27.89 M(-113.1%) | -$13.36 M(-11.0%) | -$27.89 M(+102.9%) |
| Sept 2004 | - | -$15.01 M(-4124.4%) | -$13.75 M(-981.3%) |
| June 2004 | - | $373.00 K(+258.7%) | $1.56 M(-98.8%) |
| Mar 2004 | - | $104.00 K(-86.8%) | $127.01 M(-40.5%) |
| Dec 2003 | $213.47 M(+5446.1%) | $785.00 K(+163.4%) | $213.47 M(-0.5%) |
| Sept 2003 | - | $298.00 K(-99.8%) | $214.51 M(-0.5%) |
| June 2003 | - | $125.82 M(+45.3%) | $215.60 M(+138.1%) |
| Mar 2003 | - | $86.57 M(+4643.3%) | $90.54 M(+2252.4%) |
| Dec 2002 | $3.85 M(-97.5%) | $1.82 M(+31.0%) | $3.85 M(-96.5%) |
| Sept 2002 | - | $1.39 M(+83.5%) | $108.83 M(-0.5%) |
| June 2002 | - | $759.00 K(-693.0%) | $109.38 M(-27.9%) |
| Mar 2002 | - | -$128.00 K(-100.1%) | $151.61 M(-0.9%) |
| Dec 2001 | $152.99 M(+1921.8%) | $106.81 M(+5414.2%) | $152.99 M(+228.9%) |
| Sept 2001 | - | $1.94 M(-95.5%) | $46.51 M(-4.7%) |
| June 2001 | - | $42.99 M(+3342.3%) | $48.82 M(+713.3%) |
| Mar 2001 | - | $1.25 M(+277.3%) | $6.00 M(-20.7%) |
| Dec 2000 | $7.57 M(-92.1%) | $331.00 K(-92.2%) | $7.57 M(+3.3%) |
| Sept 2000 | - | $4.25 M(+2342.0%) | $7.33 M(-90.1%) |
| June 2000 | - | $174.00 K(-93.8%) | $73.78 M(-25.1%) |
| Mar 2000 | - | $2.81 M(+3025.6%) | $98.55 M(+3.0%) |
| Dec 1999 | $95.69 M(+385.7%) | $90.00 K(-99.9%) | $95.69 M(+0.1%) |
| Sept 1999 | - | $70.70 M(+183.4%) | $95.60 M(+283.9%) |
| June 1999 | - | $24.94 M(<-9900.0%) | $24.90 M(<-9900.0%) |
| Mar 1999 | - | -$43.00 K | -$43.00 K |
| Dec 1998 | $19.70 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual cash flow from financing activities?
- What is the all time high annual CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual CFF year-on-year change?
- What is BioMarin Pharmaceutical quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly CFF year-on-year change?
- What is BioMarin Pharmaceutical TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM CFF year-on-year change?
What is BioMarin Pharmaceutical annual cash flow from financing activities?
The current annual CFF of BMRN is -$18.73 M
What is the all time high annual CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual cash flow from financing activities is $925.72 M
What is BioMarin Pharmaceutical annual CFF year-on-year change?
Over the past year, BMRN annual cash flow from financing activities has changed by -$77.00 K (-0.41%)
What is BioMarin Pharmaceutical quarterly cash flow from financing activities?
The current quarterly CFF of BMRN is -$499.13 M
What is the all time high quarterly CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly cash flow from financing activities is $914.79 M
What is BioMarin Pharmaceutical quarterly CFF year-on-year change?
Over the past year, BMRN quarterly cash flow from financing activities has changed by -$498.34 M (-63240.74%)
What is BioMarin Pharmaceutical TTM cash flow from financing activities?
The current TTM CFF of BMRN is -$518.47 M
What is the all time high TTM CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM cash flow from financing activities is $962.83 M
What is BioMarin Pharmaceutical TTM CFF year-on-year change?
Over the past year, BMRN TTM cash flow from financing activities has changed by -$499.77 M (-2672.84%)